Xtandi (generic name: enzalutamide) is an oral medication used in the treatment of prostate cancer. It specifically targets metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). This drug is classified as an androgen receptor inhibitor, which works by blocking the effects of androgens (male hormones) that can promote the growth of prostate cancer cells.